Pay-For-Delay Deals Hit 7-Year High In 2010: FTC
The number of so-called pay-for-delay deals between name-brand pharmaceutical companies and their generics competitors jumped by 60 percent in 2010, covering nearly two dozen drugs with $9.3 billion in U.S. sales,...To view the full article, register now.
Already a subscriber? Click here to view full article